Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

COMPLETED

NCT02809560

Detection of Cav1 Calcium Channels in Inflammatory Cells of Asthmatic Children

Sponsor: University Hospital, Toulouse

View on ClinicalTrials.gov

Summary

Asthma affects about 10% of children and 6% of adults in industrialized countries. Lymphocytes (L) Th2, a T cell population (LT) producing interleukin (IL) -4, 5 and 13 are broadly involved in this pathology in experimental models and in humans. Many studies show that the signaling pathways activated by the commitment of T receiver differ depending LT. The identification of specific signaling pathways links to Th2 offer new therapeutic approaches. Precedent study showed that mouse Th2 selectively expressed related to calcium channels sensitive channels Cav1 voltage, normally found in excitable cells where they are defined as receivers dihydropyridine (DHP). The goal of the present study is to show the presence of Cav1 channels in inflammatory cells in allergic asthmatics and show overexpression of these channels in the peripheral blood mononuclear cells from asthmatic subjects before and / or after stimulation with the TCR in comparison with controls.

Key Details

Gender

All

Age Range

6 Years - 18 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2013-03

Completion Date

2016-05

Last Updated

2026-09-21

Healthy Volunteers

Yes

Conditions

Asthma

Interventions

PROCEDURE

Induced sputum method using hypertonic serum

Collection of expectoration in sterile vial, conserved in ice all along the examination

Inclusion Criteria: For Asthmatic children arm : * Girl not in childbearing potential or taking contraceptive treatment * Asthma diagnosis in at least 6 months as defined by clinical symptoms (expiratory dyspnea, wheezing, sibilance) and respiratory function (reversibility of VEMS at least 12% after salbutamol administration) * Allergologic tests positives to airborne allergens : positive prick test and/or specific IgE \> 0,35 kU/L for at least one allergen * Asthma severity between mild to moderate based on Global initiative for asthma classification during more than one month with inhaled corticotherapies +/- long term action beta -mimetic long compounds (salmeterol, formoterol) * Patient insured with a social security scheme For control children arm : * Girl not in childbearing potential or taking contraceptive treatment * No medical history of asthma * No medical history of allergy or symptoms of allergy on skin (atopic dermatitis), respiratory tract (rhino-conjunctivitis, asthma) or food allergy Exclusion Criteria: For both arms: * Chronic respiratory pathology : known occlusive or restrictive respiratory syndrome like interstitial lung disease, neuromuscular disease, mucoviscidoses, respiratory tract abnormalities with cough, dyspnea or digital hippocratism. * History of pulmonary or nose and throat infectious disease during last 4 months * Parasitic disease non treated during last 3 months * Dyspnea during the inclusion * Systemic corticotherapy during the last 3 months before inclusion * Immunosuppressive therapy during the last 3 months before inclusion * Diabeta * Disease causing immune disorder * Infection during inclusion * Participation to another study witch implies medical treatment during last 3 months before inclusion For asthmatic children arm : * Chronic pulmonary pathology (excluding asthma) * Asthma exacerbation during inclusion * VEMS \< 70% of normal range or VEMS \< 70% of normal range after inhalation of serum (despite salbutamol administration) * Patient unable to complete pulmonary function testing

Locations (1)

Centre Hospitalier Universitaire

Toulouse, France